Core Viewpoint - Xiansheng Pharmaceutical (02096) has seen a stock increase of over 3%, currently trading at HKD 12.61 with a transaction volume of HKD 22.0187 million, following the announcement of an overseas licensing option agreement with AbbVie Inc. for the investigational drug SIM0500 [1] Group 1 - The agreement with AbbVie includes an upfront payment and potential milestone payments totaling up to USD 1.055 billion, along with tiered royalties based on net sales [1] - Xiansheng Pharmaceutical's core product SIM0500 has received a USD 40 million milestone payment from AbbVie, and the drug has been granted Fast Track designation by the FDA [1] - The company is expected to report Phase I clinical data and achieve proof of concept within the year, indicating strong progress in its innovative research and development capabilities [1] Group 2 - SIM0500 has demonstrated significantly superior anti-tumor activity compared to dual-antibody TCEs in preclinical studies and is leading in global progress among competitors targeting the same pathway [1] - The company has successfully established multiple overseas licensing collaborations valued at USD 1 billion, showcasing its robust platform technology and innovation in drug development [1]
先声药业涨超3% 近日核心产品SIM0500获艾伯维4000万美元里程碑付款